首页> 外文期刊>Oncology reports >BreastDefend? prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer
【24h】

BreastDefend? prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer

机译:乳房防御?预防三阴性人类乳腺癌的原位动物模型中的乳腺癌到肺癌的转移

获取原文
获取原文并翻译 | 示例
           

摘要

We have recently demonstrated that a natural dietary supplement BreastDefend (BD), which contains extracts from medicinal mushrooms (Coriolus versicolor, Ganoderma lucidum, Phellinus linteus), medicinal herbs (Scutellaria barbata, Astragalus membranaceus, Curcuma longa), and purified biologically active nutritional compounds (diindolylmethane and quercetin), inhibits proliferation and metastatic behavior of MDA-MB-231 invasive human breast cancer cells in vitro. In the present study, we evaluated whether BD suppresses growth and breast-to lung cancer metastasis in an orthotopic model of human breast cancer cells implanted in mice. Oral application of BD (100 mg/kg of body weight for 4 weeks) by intragastric gavage did not affect body weight or activity of liver enzymes and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. Moreover, BD significantly decreased the change in tumor volume over time compared to the control group (p=0.002). BD treatment also markedly decreased the incidence of breast-to-lung cancer metastasis from 67% (control) to 20% (BD) (p<0.05) and the number of metastases from 2.8 (0.0, 48.0) in the control group to 0.0 (0.0, 14.2) in the BD treatment group (p<0.05). Finally, anti-metastatic activity of BD in vivo was further confirmed by the downregulation of expression of PLAU (urokinase plasminogen activator, uPA) and CXCR4 (C-X-C chemokine receptor-4) genes in breast tumors. In conclusion, BD may be considered as a biological therapeutic agent against invasive breast cancers.
机译:我们最近证明,天然膳食补充剂BreastDefend(BD),其中包含药用蘑菇(云芝,灵芝,桑黄),药用植物(黄S,黄芪,姜黄,姜黄)的提取物,以及纯化的具有生物活性的营养化合物(二吲哚基甲烷和槲皮素)在体外抑制MDA-MB-231侵袭性人乳腺癌细胞的增殖和转移行为。在本研究中,我们评估了BD是否抑制植入小鼠体内的人类乳腺癌细胞的原位模型中的生长以及从乳腺癌到肺癌的转移。胃内灌胃口服BD(100 mg / kg体重,持续4周)对体重或肝酶活性没有影响,对小鼠的肝,脾,肾,肺和心脏组织均无毒性迹象。此外,与对照组相比,BD显着降低了肿瘤体积随时间的变化(p = 0.002)。 BD治疗还使乳腺癌至肺癌转移的发生率从67%(对照组)显着降低到20%(BD)(p <0.05),转移数量从对照组的2.8(0.0,48.0)降低到0.0 BD治疗组(0.0,14.2)(p <0.05)。最后,乳腺肿瘤中PLAU(尿激酶纤溶酶原激活物,uPA)和CXCR4(C-X-C趋化因子受体4)基因的表达下调进一步证实了BD在体内的抗转移活性。总之,BD可以被认为是针对浸润性乳腺癌的生物治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号